tp-6076
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2018 (NCT03691584)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- 30S ribosomal protein S12INHIBITOR
rpsL inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCN(CC)[C@@H]1C(=O)C(C(N)=O)=C[C@@]2(O)C(=O)C3=C(O)c4c(O)cc([C@@H]5CCCN5)c(C(F)(F)F)c4C[C@H]3C[C@@H]12- Mol. weight
- 563.57 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068527 ↗
Also known as
- tp-6076
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03691584 | Phase 1 | Nov 30, 2018 | Pharmaceutical Research Associates, Inc. (PRA), Tetraphase Pharmaceuticals |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2018 |
| Tetraphase Pharmaceuticals | For profit | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1